- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841619
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus
Study Overview
Detailed Description
The ultimate goal of this pilot project is to generate proof-of-concept data showing that treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients. This project has relevant clinical implications due to the severe side effects of and lack of response to current therapies.
From the review of literature, it can be postulated that:
- the beneficial effects of IVIg for patients with CLE should be prompt, with marked improvement within a few weeks;
- clinical improvement should last several weeks after the last infusion; and
- remission may be prolonged by maintenance IVIg therapy.
Although this is only a non-controlled study, the investigator expects that IVIg will improve CLE, including those resistant to standard treatments. It is anticipated that treatment with IVIg will facilitate healing of extensive cutaneous lesions and achieve rapid remission. Maintenance therapy with repeated monthly pulses of IVIg is expected to keep the disease in remission during the treatment-free follow up observational period. The results will provide the basis a multicenter randomized controlled study to identify which CLE subsets will benefit the most and which protocol will provide the optimal clinical outcome.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92697
- The Institute for Clinical and Translational Science (ICTS)
-
Irvine, California, United States, 92697
- Unversity of California, Irvine Healthcare, Dermatology, Gottschalk Medical Plaza
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Be at least 18 years of age at time of informed consent.
- Have had a diagnosis of CLE
- Currently has active CLE (any subtype) established by standard clinical and histo- and immunopathologic criteria
- Falls into one of the two following cohorts:
- Cohort 1 - Has received a standard systemic therapy without a therapeutic response for a minimum of one month
- Cohort 2 - Has not received any systemic treatment
Exclusion Criteria:
- Subject is not over 18 years of age.
- Subject cannot understand or follow directions.
- Subject is a female of child-bearing potential and unwilling to use a form of highly effective birth control.
- Subject is pregnant, planning to get pregnant, or breast feeding.
- Subject has a known history of immunoglobulin A (IgA) deficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: IVIg as a monotherapy
IVIg will be used as a first line treatment.
Topical treatment will be stopped at the beginning of IVIg therapy.
|
All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE.
The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine.
After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse.
In the case of relapse, which is expected to occur in <25% subjects, the subjects will be re-treated by the standard protocol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS)
Time Frame: Initial, 1st Visit - 9th Visit
|
Disease activity will be measured using the CLASI activity score that describes the activity of the disease. This score ranges from 0-70, with higher scores indicating more severe skin disease. This clinical assessment tool enables standardized assessments of response to therapy. Results expressed relative to the mean initial value of all patients, taken as 100%. Each proceeding visit will be relative to the initial visit. A decrease in percentage represents improvement while an increase in percentage indicates worsening of CLE. Visits occur on a month-to-month basis. |
Initial, 1st Visit - 9th Visit
|
Skindex 29
Time Frame: Initial, 1st Visit - 9th Visit
|
The subjects also evaluated their skin-specific quality of life with the Skindex-29 - the questionnaire consisting of 29 items used to calculate three subscales: symptoms (pain, itch, burning, sensitivity), emotions (depression, anxiety, embarrassment, anger) and functioning (sleep, relationships with others).
All assessments were repeated at all study visits.
Results expressed relative to the mean initial value of all patients, taken as 100%.
Each proceeding visit will be relative to the initial visit.
A decrease in percentage represents improvement while an increase in percentage indicates worsening of CLE.
Visits occur on a month-to-month basis.
|
Initial, 1st Visit - 9th Visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Change in Physician's Subjective Assessment of Improvement (PSAI)
Time Frame: Initial, 1st Visit - 9th Visit
|
At clinic visits, the investigator will categorize the change in disease activity in each patient as improved, unchanged, or worse since the last visit. Estimated change in disease activity will be based on the investigator's subjective assessment of the patient's skin disease. Results expressed relative to the mean initial value of all patients, taken as 100%. Each proceeding visit will be relative to the initial visit. A decrease in percentage represents improvement while an increase in percentage indicates worsening of CLE. Visits occur on a month-to-month basis. |
Initial, 1st Visit - 9th Visit
|
Mean Percent Change in Physician's Subjective Assessment of Severity (PSAS)
Time Frame: Initial, 1st Visit - 9th Visit
|
At clinic visits, the investigator will categorize the change in disease activity in each patient as improved, unchanged, or worse since the last visit. Estimated change in disease activity will be based on the investigator's subjective assessment of the patient's skin disease. Results expressed relative to the mean initial value of all patients, taken as 100%. Each proceeding visit will be relative to the initial visit. A decrease in percentage represents improvement while an increase in percentage indicates worsening of CLE. Visits occur on a month-to-month basis. |
Initial, 1st Visit - 9th Visit
|
Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Damage Score (CLASI - TDS)
Time Frame: Initial, 1st Visit - 9th Visit
|
Disease activity will be measured using the CLASI activity score that describes the damage of the disease. This score ranges from 0-70, with higher scores indicating more severe skin disease. This clinical assessment tool enables standardized assessments of response to therapy. Results expressed relative to the mean initial value of all patients, taken as 100%. Each proceeding visit will be relative to the initial visit. A decrease in percentage represents improvement while an increase in percentage indicates worsening of CLE. Visits occur on a month-to-month basis. All patients were measured identically in all visits. |
Initial, 1st Visit - 9th Visit
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sergei Grando, MD PhD D.Sc., University of California, Irvine
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-9351
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Lupus Erythematosus
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Puerto Rico, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hunga... and more
-
BiogenEnrolling by invitationSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusSpain, United States, Sweden
-
Bristol-Myers SquibbRecruitingLupus Erythematosus, Discoid | Lupus Erythematosus, Subacute CutaneousUnited States, Mexico, Russian Federation, Australia, Argentina, Poland, France, Germany, Taiwan
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
University of PennsylvaniaRecruitingCutaneous Lupus Erythematosus (CLE)United States
-
Novartis PharmaceuticalsCompletedSubacute Cutaneous Lupus ErythematosusGreece, Germany, Italy
-
Gilead SciencesRecruitingCutaneous Lupus Erythematosus (CLE)United States, Spain, Czechia, Germany
-
University of PennsylvaniaCelgene CorporationCompletedCutaneous Lupus Erythematosus (CLE)United States
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
BiogenCompletedSystemic Lupus Erythematosus | Active Cutaneous Lupus ErythematosusUnited States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
Clinical Trials on IVIg
-
Tabriz University of Medical SciencesCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Vanderbilt University Medical CenterCSL BehringRecruiting
-
Tabriz University of Medical SciencesCompletedRecurrent Pregnancy LossIran, Islamic Republic of
-
Novartis PharmaceuticalsCompleted
-
Azidus BrasilSichuan Yuanda Shuyang Pharmaceutical Co., Ltd.Not yet recruitingPrimary Immunodeficiency Disease
-
Shanghai Changzheng HospitalNot yet recruitingBacteremia | Viremia | Acute Rejection of Renal Transplant
-
Assistance Publique - Hôpitaux de ParisUnknownAutoimmune Diseases | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Clarkson Syndrome | Muscular Autoimmune DisordersFrance
-
Hormozgan University of Medical SciencesCompletedNeonatal SepsisIran, Islamic Republic of
-
University of South FloridaBaxter Healthcare CorporationCompletedSpinocerebellar AtaxiaUnited States
-
National Institute of Neurological Disorders and...CompletedMuscle Rigidity | Spasm | Stiff Man SyndromeUnited States